Genomic Health (FRA:G7H) Retained Earnings : €-171.4 Mil (As of Sep. 2019)

View and export this data going back to . Start your Free Trial

What is Genomic Health Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Genomic Health's retained earnings for the quarter that ended in Sep. 2019 was €-171.4 Mil.

Genomic Health's quarterly retained earnings declined from Mar. 2019 (€-171.1 Mil) to Jun. 2019 (€-183.6 Mil) but then increased from Jun. 2019 (€-183.6 Mil) to Sep. 2019 (€-171.4 Mil).

Genomic Health's annual retained earnings increased from Dec. 2016 (€-229.5 Mil) to Dec. 2017 (€-207.8 Mil) and increased from Dec. 2017 (€-207.8 Mil) to Dec. 2018 (€-181.4 Mil).

Genomic Health Retained Earnings Historical Data

The historical data trend for Genomic Health's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomic Health Retained Earnings Chart

Genomic Health Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Retained Earnings

Get a 7-Day Free Trial

-158.03

-209.46

-229.50

-207.82

-181.36

Genomic Health Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Retained Earnings	Get a 7-Day Free Trial															-184.46	-181.36	-171.09	-183.59	-171.39

Genomic Health Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Genomic Health (FRA:G7H) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Genomic Health (FRA:G7H) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genomic Health Inc (FRA:G7H) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

301 Penobscot Drive, Redwood City, CA, USA, 94063

Website

http://www.genomichealth.com

Genomic Health Inc provides genomic-based diagnostic tests that focus on the treatment of early-stage cancer. The firm's Oncotype DX tests analyze the expression levels of genes in tumor tissue samples and provide a numeric score that physicians can use to determine the aggressiveness of breast, colon, or prostate cancer. These test results can guide decisions about the use of chemotherapy, radiation, surgery, or other aggressive treatments. The Oncotype DX breast cancer test generates the majority of the firm's revenue, analyzing 21 genes to determine the optimal treatment for stage I, II, or IIa breast cancer. The majority of Genomic Health's sales occur within the United States.

Genomic Health (FRA:G7H) Headlines

No Headlines